Page last updated: 2024-11-12

desbutylbenflumetol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

desbutylbenflumetol: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9934522
MeSH IDM0400035

Synonyms (23)

Synonym
desbutylbenflumetol
desbutyl lumefantrine
355841-11-1
252990-19-5
9h-fluorene-4-methanol, .alpha.-((butylamino)methyl)-2,7-dichloro-9-((4-chlorophenyl)methylene)-, (9z)-
(z)-2-(butylamino)-1-(2,7-dichloro-9-(4-chlorobenzylidene)-9h-fluoren-4-yl)ethanol
desbutyllumefantrine
desbutyl-benflumetol
unii-07l7o84hgw
desbutyl benflumetol
9h-fluorene-4-methanol, alpha-((butylamino)methyl)-2,7-dichloro-9-((4-chlorophenyl)methylene)-, (9z)-
07l7o84hgw ,
DTXSID10433027
J-015923
desbutyl-lumefantrine
|a-[(butylamino)methyl]-2,7-dichloro-9-[(4-chlorophenyl)methylene]-9h-fluorene-4-methanol;
CS-0012431
HY-12781
AS-6171
Q27236316
AKOS037645608
9h-fluorene-4-methanol,a-[(butylamino)methyl]-2,7-dichloro-9-[(4-chlorophenyl)methylene]-,(9z)-
2-(butylamino)-1-[(9z)-2,7-dichloro-9-(4-chlorobenzylidene)-9h-fluoren-4-yl]ethanol

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"The pharmacodynamic interaction between lumefantrine and monodesbutyl-benflumetol has been investigated in 44 fresh isolates of patients with a Plasmodium falciparum infection from the region of Mae Sot (Thailand)."( Pharmacodynamic interaction between lumefantrine and desbutyl-benflumetol in Plasmodium falciparum in vitro.
Congpuong, K; Leeb, A; Satimai, W; Wernsdorfer, G; Wernsdorfer, WH; Wiedermann, U, 2010
)
0.36
" A simultaneous pharmacokinetic drug-metabolite model was developed based on dense venous and sparse capillary lumefantrine and desbutyl-lumefantrine plasma samples from 116 pregnant patients on the Thailand-Myanmar border."( Lumefantrine and Desbutyl-Lumefantrine Population Pharmacokinetic-Pharmacodynamic Relationships in Pregnant Women with Uncomplicated Plasmodium falciparum Malaria on the Thailand-Myanmar Border.
Blessborn, D; Day, NP; Hanpithakpong, W; Kloprogge, F; McGready, R; Nosten, F; Tarning, J; White, NJ, 2015
)
0.42
" The aim of this study was to investigate the pharmacokinetic and pharmacodynamic properties of lumefantrine and the pharmacokinetic properties of its metabolite, desbutyl-lumefantrine, in order to inform optimal dosing regimens in all patient populations."( Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis.
Ashley, EA; Ashton, M; Aweeka, F; Bakshi, R; Barnes, KI; Björkman, A; Borrmann, S; Checchi, F; Davis, TME; Deloron, P; Ezzet, F; Faucher, JF; Fogg, C; Friberg Hietala, S; Guerin, PJ; Hamed, K; Karbwang, J; Karunajeewa, H; Kloprogge, F; Kofoed, PE; Lefèvre, G; Mårtensson, A; Mayxay, M; McGready, R; Mwai, L; Newton, PN; Ngasala, B; Nosten, F; Parikh, S; Piola, P; Price, RN; Proux, S; Salman, S; Stepniewska, K; Tarning, J; Tékété, M; Ursing, J; van Vugt, M; White, NJ; Workman, L, 2018
)
0.48
" The developed lumefantrine population pharmacokinetic model was used for dose optimisation through in silico simulations."( Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis.
Ashley, EA; Ashton, M; Aweeka, F; Bakshi, R; Barnes, KI; Björkman, A; Borrmann, S; Checchi, F; Davis, TME; Deloron, P; Ezzet, F; Faucher, JF; Fogg, C; Friberg Hietala, S; Guerin, PJ; Hamed, K; Karbwang, J; Karunajeewa, H; Kloprogge, F; Kofoed, PE; Lefèvre, G; Mårtensson, A; Mayxay, M; McGready, R; Mwai, L; Newton, PN; Ngasala, B; Nosten, F; Parikh, S; Piola, P; Price, RN; Proux, S; Salman, S; Stepniewska, K; Tarning, J; Tékété, M; Ursing, J; van Vugt, M; White, NJ; Workman, L, 2018
)
0.48

Dosage Studied

ExcerptRelevanceReference
" The aim of this study was to investigate the pharmacokinetic and pharmacodynamic properties of lumefantrine and the pharmacokinetic properties of its metabolite, desbutyl-lumefantrine, in order to inform optimal dosing regimens in all patient populations."( Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis.
Ashley, EA; Ashton, M; Aweeka, F; Bakshi, R; Barnes, KI; Björkman, A; Borrmann, S; Checchi, F; Davis, TME; Deloron, P; Ezzet, F; Faucher, JF; Fogg, C; Friberg Hietala, S; Guerin, PJ; Hamed, K; Karbwang, J; Karunajeewa, H; Kloprogge, F; Kofoed, PE; Lefèvre, G; Mårtensson, A; Mayxay, M; McGready, R; Mwai, L; Newton, PN; Ngasala, B; Nosten, F; Parikh, S; Piola, P; Price, RN; Proux, S; Salman, S; Stepniewska, K; Tarning, J; Tékété, M; Ursing, J; van Vugt, M; White, NJ; Workman, L, 2018
)
0.48
" Simulations using the lumefantrine pharmacokinetic model suggest that, in young children and pregnant women beyond the first trimester, lengthening the dose regimen (twice daily for 5 days) and, to a lesser extent, intensifying the frequency of dosing (3 times daily for 3 days) would be more efficacious than using higher individual doses in the current standard treatment regimen (twice daily for 3 days)."( Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis.
Ashley, EA; Ashton, M; Aweeka, F; Bakshi, R; Barnes, KI; Björkman, A; Borrmann, S; Checchi, F; Davis, TME; Deloron, P; Ezzet, F; Faucher, JF; Fogg, C; Friberg Hietala, S; Guerin, PJ; Hamed, K; Karbwang, J; Karunajeewa, H; Kloprogge, F; Kofoed, PE; Lefèvre, G; Mårtensson, A; Mayxay, M; McGready, R; Mwai, L; Newton, PN; Ngasala, B; Nosten, F; Parikh, S; Piola, P; Price, RN; Proux, S; Salman, S; Stepniewska, K; Tarning, J; Tékété, M; Ursing, J; van Vugt, M; White, NJ; Workman, L, 2018
)
0.48
"Our findings suggest that revised AL dosing regimens for young children and pregnant women would improve drug exposure but would require longer or more complex schedules."( Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis.
Ashley, EA; Ashton, M; Aweeka, F; Bakshi, R; Barnes, KI; Björkman, A; Borrmann, S; Checchi, F; Davis, TME; Deloron, P; Ezzet, F; Faucher, JF; Fogg, C; Friberg Hietala, S; Guerin, PJ; Hamed, K; Karbwang, J; Karunajeewa, H; Kloprogge, F; Kofoed, PE; Lefèvre, G; Mårtensson, A; Mayxay, M; McGready, R; Mwai, L; Newton, PN; Ngasala, B; Nosten, F; Parikh, S; Piola, P; Price, RN; Proux, S; Salman, S; Stepniewska, K; Tarning, J; Tékété, M; Ursing, J; van Vugt, M; White, NJ; Workman, L, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's9 (56.25)29.6817
2010's7 (43.75)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (12.50%)5.53%
Reviews1 (6.25%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (81.25%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]